Innovating Tomorrow's Medicine

What if we could stop disease-causing proteins before they're even made—using small molecules to target their mRNA? David Weitz, CEO of Syrna Therapeutics, is pioneering exactly that: 3D structure-guided drug discovery for mRNA, coupled with covalent translation inhibitors that silence proteins at the source. 🎙️ Full episode drops 7 January 2026 In the complete interview, we dive into: • Why m...

What if we could silence disease-causing proteins not by targeting the protein itself, but by preventing its mRNA from ever being translated—using small-molecule drugs? In this episode, David Weitz, Co-founder, President and CEO of Syrna Therapeutics, shares how his company is pioneering a revolutionary approach: 3D structure-guided drug discovery for mRNA, coupled with covalent translation inhibi...

What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start. In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his company is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far. What we discuss: • How proteomic signatures differentiate responders fro...

What if you could know before enrolling a single patient which ones will actually respond to treatment? Pilgrim Jackson, CEO of Yatiri Bio, is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far—potentially cutting Phase 2 trials from 100 patients to just 40. 🎙️ Full episode drops December 18 In the complete interview, we dive into: • Proteomic signat...

What if we could help millions quit smoking with a naturally derived compound that's been used for decades—but never brought to the U.S. market until now? In this episode, Rick Stewart, CEO of Achieve Life Sciences, shares how cytisinicline is redefining smoking cessation after receiving FDA acceptance for its New Drug Application (NDA)—a major milestone in the fight against nicotine dependenc...

What if a naturally derived compound used for decades overseas could finally transform smoking cessation in the U.S.? Rick Stewart, CEO of Achieve Life Sciences, just received FDA acceptance for cytisinicline's NDA—a major milestone that could help millions quit smoking. 🎙️ Full episode drops December 4 In the complete interview, we dive into: • FDA NDA acceptance and what comes next • Commerc...

What if the key to biotech success isn't just science and strategy—but self-awareness and spiritual practice? In this episode, Dr. Sheila Gujrathi—biotech entrepreneur, executive, and drug developer with over 25 years of experience—shares insights from her Amazon bestselling book The Mirror Effect, exploring how intentional leadership transforms both business outcomes and organizational cultur...

What if the key to biotech success isn't just science and strategy—but self-awareness and spiritual practice? Dr. Sheila Gujrathi—who led the development of Orencia® and Nulojix®—shares insights from her Amazon bestselling book The Mirror Effect, exploring how intentional leadership transforms both business outcomes and organizational culture. 🎙️ Full episode drops November 20 In the complete...

What if we could bring the power of precision medicine to more cancer patients, faster—using AI to match patients with the right treatments at the right time? In this episode, Rick Fultz, CEO of Acurion, shares how his company is transforming precision oncology by combining next-generation science with artificial intelligence to deliver personalized cancer care at scale. What we discuss: • The vis...

What if AI could match cancer patients with the right treatments faster—bringing precision medicine to more people who need it? Rick Fultz, CEO of Acurion, is using artificial intelligence to transform how we select cancer therapies, moving beyond traditional biomarkers to comprehensive patient profiling. 🎙️ Full episode drops October 30 In the complete interview, we dive into: How AI is revolutio...

What if we could use gene editing to treat Duchenne Muscular Dystrophy—not just manage symptoms, but address the underlying genetic cause in a scalable, precise way? In this episode, Dr. Courtney Young, CEO of MyoGene Bio, shares how her company is using CRISPR technology to transform the treatment landscape for Duchenne Muscular Dystrophy, offering hope to patients and families facing this devast...

What if gene editing could treat Duchenne Muscular Dystrophy at its genetic root—not just manage symptoms? Dr. Courtney Young, CEO of MyoGene Bio, is using CRISPR to address the underlying cause of Duchenne in a scalable, precise way that could transform rare disease treatment. 🎙️ Full episode drops September 11 In the complete interview, we dive into: • Why CRISPR is uniquely suited for Duchenne...

What if we could destroy cancer cells using a completely novel payload—one that doesn't rely on traditional chemotherapy or even antibody-drug conjugates, but instead uses lytic peptides to obliterate tumors? In this episode, Dr. Stanley Lewis, CEO of A28 Therapeutics, shares how his company is pioneering lytic peptides as a next-generation cancer therapy, offering a fundamentally different ap...

What if we could destroy cancer cells using a completely novel payload that doesn't rely on traditional chemotherapy or even antibody-drug conjugates? Dr. Stanley Lewis, CEO of A28 Therapeutics, is pioneering lytic peptides as a next-generation cancer therapy—a fundamentally different way to kill tumors. 🎙️ Full episode drops August 28 In the complete interview, we dive into: • How lytic pepti...

What if we could transform the treatment landscape for rheumatologic diseases by taking bold, innovative approaches that go beyond incremental improvements? In this episode, Dr. James Mackay, CEO of Crystalys Therapeutics, shares the vision behind launching a new biotech company focused on rheumatology, combining next-generation science with strategic leadership to address unmet patient needs. Wha...

What does it take to launch a biotech company with bold, innovative approaches to rheumatologic diseases? Dr. James Mackay, CEO of Crystalys Therapeutics, is bringing next-generation science and strategic leadership to patients who desperately need better treatment options. 🎙️ Full episode drops August 14 In the complete interview, we dive into: • The vision behind Crystalys Therapeutics • New app...

What does it take to transform bold ideas into real-world treatments that save lives? Welcome to Innovating Tomorrow's Medicine, a podcast that goes beyond the headlines to explore the strategies, insights, and breakthroughs shaping the future of healthcare and biotechnology. Hosted by Dr. Jeff Trickett—a neuroscientist and biotech strategist—this show features candid conversations with biotec...